Market cap, ratios, CAGR and revenue: company table snapshot as of 30 Oct 2026 (the same figures on every page). Price: snapshot as of 30 Oct 2026. Not investment advice.
Where it fits
Formulates and aseptically fills sterile products - vials, ampoules, bags, prefilled syringes and pens - for hospitals and specialty pharmacies, either under own labels or as contract fill-finish for other companies.
Why it matters
Injectables are where US shortages concentrate and competition is thinner than in oral solids, so margins are better and erosion slower. They are also the hardest plants to keep compliant: most recent USFDA warning letters on Indian sites have been at sterile facilities.
Where the value pool sits
20-35% EBITDA margins for scaled, compliant players; capex is heavy (isolator lines, lyophilisers) and approvals slow. GLP-1 peptides, oncology and biosimilars are pulling fill-finish demand up globally.
Key drivers
US drug shortages in hospital injectables
GLP-1 and peptide fill-finish demand
Biosimilar launches needing prefilled syringes
Contract fill-finish for global innovators
Potential bottlenecks
Aseptic compliance - sterility assurance and data integrity are frequent 483 findings
Long build and validation times for new sterile lines
Glass and component supply (vials, stoppers, cartridges)